Physician profile
Bethanne Smith
NPI 1275704504
$2,468.20
in general payments reported to CMS, 2019-2025
21 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $328 · 2023: $348 · 2024: $323 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470 · Travel and Lodging: $314 · Education: $61.99 · Gift: $47.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.98 |
| Travel and Lodging | $313.88 |
| Education | $61.99 |
| Gift | $47.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $849.89 | 2022-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $241.78 | 2021-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $213.76 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $167.47 | 2021-2025 | General - Therapies, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Merck Sharp & Dohme LLC | $127.63 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $122.74 | 2022-2024 | Atacand, Farxiga |
| Abiomed | $116.22 | 2024-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.11 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $103.00 | 2021-2022 | |
| Abbott Laboratories | $70.13 | 2021-2023 | Amplatzer Amulet |
| Astellas Pharma US INC | $64.99 | 2021 | |
| Biotronik INC. | $51.00 | 2021 | |
| Amgen INC. | $50.49 | 2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $29.41 | 2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $27.40 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.90 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $22.44 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $20.88 | 2022 | |
| Novo Nordisk INC | $18.78 | 2024 | Ozempic |
| Novartis Pharmaceuticals Corporation | $15.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.34 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethanne Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.